Healthcare / Drug Manufacturers - Specialty & GenericTel Aviv
$45.00
+12.60 (+33.07%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 15%
FCF escenarios
weak_data · normalized FCF $-3.4M · quality 31.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
6/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$36M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-42.6%
↓Gross Margin
8.3%
↓Debt/Equity
1.22
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-180.9%
FCF / Net income
1.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.6M · net income $-6.1M · FCF $-6.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.6M | $3.6M | $3.2M | $7.6M | — |
| Net Income | $-6.1M | $-6.1M | $-8.8M | $1.9M | $-5.6M |
| EBITDA | $-9.6M | $-9.6M | $-6.5M | $-5.7M | $-5.9M |
| EPS | — | — | -0.17 | 0.17 | -0.20 |
| Gross Margin | 8.3% | 8.3% | -22.4% | 15.1% | — |
| Operating Margin | -226.5% | -226.5% | -169.7% | -69.8% | — |
| Net Margin | -168.5% | -168.5% | -273.5% | 24.8% | — |
| Balance Sheet | |||||
| Debt/Equity | 1.22 | 1.22 | -0.60 | -0.13 | -0.37 |
| Current Ratio | 0.06 | 0.06 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.5M | $-6.5M | $649000.00 | $-3.4M | $-6.0M |
| Returns | |||||
| ROE | -42.6% | -42.6% | 43.9% | -65.3% | 624.6% |
| Valuation | |||||
| P/B | 256.50 | 256.50 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 11.6% | 11.6% | -57.7% | — | — |
| EPS Growth | — | — | -200.0% | 185.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-35.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.17 → n/d
Residual
-35.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.